Literature DB >> 22759798

Prognostic impact of the addition of peak oxygen consumption to the Seattle Heart Failure Model in a transplant referral population.

Wayne C Levy1, Keith D Aaronson, Todd F Dardas, Paula Williams, Jennifer Haythe, Donna Mancini.   

Abstract

BACKGROUND: In this study we investigated whether the addition of peak oxygen consumption (VO(2)) improves the predictive accuracy of the Seattle Heart Failure Model (SHFM). The SHFM is a validated multivariate risk model that uses NYHA classification to assess functional capacity rather than peak oxygen consumption (VO(2)).
METHODS: Outpatients (n = 1,240) evaluated for transplant at three centers had their SHFM score calculated and peak VO(2) measured. The outcomes assessed were death/LVAD/urgent transplant with censoring at the time of elective transplant.
RESULTS: Over the course of 4.0 (mean) years of observation, there were 571 events. Both the SHFM score (χ(2) = 227) and peak VO(2) (χ(2) = 88, both p < 0.0001) were highly predictive of outcomes. The SHFM and peak VO(2) were modestly correlated (r = 0.39, p < 0.0001). In a multivariate Cox model, peak VO(2) added to the SHFM with a hazard ratio of 0.949 (p < 0.0001) for each 1-ml/kg/min increase. Peak VO(2) improved both the net reclassification improvement and integrated discrimination index (both p ≤ 0.0002). Peak VO(2) provided additive prognostic information within each SHFM score (p < 0.05). The 1-year areas under the receiver-operating characteristic curve were obtained for peak VO(2) (0.645, 95% CI 0.606 to 0.684), SHFM (0.758, 95% CI 0.721 to 0.795) and SHFM with peak VO(2) (0.766, 95% CI 0.731 to 0.802). The SHFM-predicted vs actual survival free of LVAD/UNOS Status 1 transplant at 1 year (86% vs 83%) and 4 years (63% vs 63%) were similar.
CONCLUSIONS: The multivariate SHFM is a powerful predictor of death/LVAD/urgent transplant. Peak VO(2) adds prognostic information across the spectrum of the SHFM, but changes in decision regarding transplant listing occur mainly in moderate-risk patients.
Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22759798     DOI: 10.1016/j.healun.2012.04.006

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

1.  Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with heart failure.

Authors:  Todd Dardas; Yanhong Li; Shelby D Reed; Christopher M O'Connor; David J Whellan; Stephen J Ellis; Kevin A Schulman; William E Kraus; Daniel E Forman; Wayne C Levy
Journal:  J Heart Lung Transplant       Date:  2015-03-26       Impact factor: 10.247

2.  The importance of physical performance in the assessment of patients on haemodialysis: A survival analysis.

Authors:  Karsten Vanden Wyngaert; Wim Van Biesen; Sunny Eloot; Amaryllis H Van Craenenbroeck; Patrick Calders; Els Holvoet
Journal:  PLoS One       Date:  2022-05-19       Impact factor: 3.752

3.  Is cardiopulmonary exercise testing essential to indicate ventricular assist device implantation in patients with INTERMACS profile 4-7?

Authors:  Teruhiko Imamura; Koichiro Kinugawa; Daisuke Nitta; Osamu Kinoshita; Kan Nawata; Minoru Ono
Journal:  J Artif Organs       Date:  2016-03-18       Impact factor: 1.731

4.  Ten-year experience with extended criteria cardiac transplantation.

Authors:  Marc D Samsky; Chetan B Patel; Ashleigh Owen; Phillip J Schulte; Jacob Jentzer; Paul B Rosenberg; G Michael Felker; Carmelo A Milano; Adrian F Hernandez; Joseph G Rogers
Journal:  Circ Heart Fail       Date:  2013-10-02       Impact factor: 8.790

5.  Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging.

Authors:  Eric S Ketchum; Arnold F Jacobson; James H Caldwell; Roxy Senior; Manuel D Cerqueira; Gregory S Thomas; Denis Agostini; Jagat Narula; Wayne C Levy
Journal:  J Nucl Cardiol       Date:  2012-09-05       Impact factor: 5.952

Review 6.  Advanced therapies for end-stage heart failure.

Authors:  Jason N Katz; Sarah B Waters; Ian B Hollis; Patricia P Chang
Journal:  Curr Cardiol Rev       Date:  2015

Review 7.  Comparison among different multiparametric scores for risk stratification in heart failure patients with reduced ejection fraction.

Authors:  Ugo Corrà; Alessandra Magini; Stefania Paolillo; Maria Frigerio
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

8.  Heart failure mortality prediction using PRISM score and development of a classification and regression tree model to refer patients for palliative care consultation.

Authors:  Sindhu Avula; Michael LaFata; Mohammed Nabhan; Ambreen Allana; Bhavana Toprani; Caleb Scheidel; Anupam Suneja
Journal:  Int J Cardiol Heart Vasc       Date:  2019-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.